The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling

Alexander I. Sankin, Abraham A. Hakimi, Nina Mikkilineni, Irina Ostrovnaya, Mikhail T. Silk, Yupu Liang, Roy Mano, Michael Chevinsky, Robert J. Motzer, Stephen B. Solomon, Emily H. Cheng, Jeremy C. Durack, Jonathan A. Coleman, Paul Russo, James J. Hsieh

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Primary clear cell renal cell carcinoma (ccRCC) genetic heterogeneity may lead to an underestimation of the mutational burden detected from a single site evaluation. We sought to characterize the extent of clonal branching involving key tumor suppressor mutations in primary ccRCC and determine if genetic heterogeneity could limit the mutation profiling from a single region assessment. Ex vivo core needle biopsies were obtained from three to five different regions of resected renal tumors at a single institution from 2012 to 2013. DNA was extracted and targeted sequencing was performed on five genes associated with ccRCC (von-Hippel Lindau [VHL], PBRM1, SETD2, BAP1, and KDM5C). We constructed phylogenetic trees by inferring clonal evolution based on the mutations present within each core and estimated the predictive power of detecting a mutation for each successive tumor region sampled. We obtained 47 ex vivo biopsy cores from 14 primary ccRCC's (median tumor size 4.5 cm, IQR 4.0-5.9 cm). Branching patterns of various complexities were observed in tumors with three or more mutations. A VHL mutation was detected in nine tumors (64%), each time being present ubiquitously throughout the tumor. Other genes had various degrees of regional mutational variation. Based on the mutations' prevalence we estimated that three different tumor regions should be sampled to detect mutations in PBRM1, SETD2, BAP1, and/or KDM5C with 90% certainty. The mutational burden of renal tumors varies by region sampled. Single site assessment of key tumor suppressor mutations in primary ccRCC may not adequately capture the genetic predictors of tumor behavior.

Original languageEnglish (US)
Pages (from-to)1485-1492
Number of pages8
JournalCancer Medicine
Volume3
Issue number6
DOIs
StatePublished - Dec 1 2014
Externally publishedYes

Fingerprint

Genetic Heterogeneity
Kidney Neoplasms
Biomarkers
Mutation
Neoplasms
Renal Cell Carcinoma
Genetic Suppression
Clonal Evolution
Large-Core Needle Biopsy
Kidney
Tumor Burden
Genes
Biopsy

Keywords

  • Biomarker
  • genetic heterogeneity
  • kidney cancer
  • renal biopsy
  • renal cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Sankin, A. I., Hakimi, A. A., Mikkilineni, N., Ostrovnaya, I., Silk, M. T., Liang, Y., ... Hsieh, J. J. (2014). The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling. Cancer Medicine, 3(6), 1485-1492. https://doi.org/10.1002/cam4.293

The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling. / Sankin, Alexander I.; Hakimi, Abraham A.; Mikkilineni, Nina; Ostrovnaya, Irina; Silk, Mikhail T.; Liang, Yupu; Mano, Roy; Chevinsky, Michael; Motzer, Robert J.; Solomon, Stephen B.; Cheng, Emily H.; Durack, Jeremy C.; Coleman, Jonathan A.; Russo, Paul; Hsieh, James J.

In: Cancer Medicine, Vol. 3, No. 6, 01.12.2014, p. 1485-1492.

Research output: Contribution to journalArticle

Sankin, AI, Hakimi, AA, Mikkilineni, N, Ostrovnaya, I, Silk, MT, Liang, Y, Mano, R, Chevinsky, M, Motzer, RJ, Solomon, SB, Cheng, EH, Durack, JC, Coleman, JA, Russo, P & Hsieh, JJ 2014, 'The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling', Cancer Medicine, vol. 3, no. 6, pp. 1485-1492. https://doi.org/10.1002/cam4.293
Sankin, Alexander I. ; Hakimi, Abraham A. ; Mikkilineni, Nina ; Ostrovnaya, Irina ; Silk, Mikhail T. ; Liang, Yupu ; Mano, Roy ; Chevinsky, Michael ; Motzer, Robert J. ; Solomon, Stephen B. ; Cheng, Emily H. ; Durack, Jeremy C. ; Coleman, Jonathan A. ; Russo, Paul ; Hsieh, James J. / The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling. In: Cancer Medicine. 2014 ; Vol. 3, No. 6. pp. 1485-1492.
@article{b7d6d7a7c0674c6ba538bbfb87529eae,
title = "The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling",
abstract = "Primary clear cell renal cell carcinoma (ccRCC) genetic heterogeneity may lead to an underestimation of the mutational burden detected from a single site evaluation. We sought to characterize the extent of clonal branching involving key tumor suppressor mutations in primary ccRCC and determine if genetic heterogeneity could limit the mutation profiling from a single region assessment. Ex vivo core needle biopsies were obtained from three to five different regions of resected renal tumors at a single institution from 2012 to 2013. DNA was extracted and targeted sequencing was performed on five genes associated with ccRCC (von-Hippel Lindau [VHL], PBRM1, SETD2, BAP1, and KDM5C). We constructed phylogenetic trees by inferring clonal evolution based on the mutations present within each core and estimated the predictive power of detecting a mutation for each successive tumor region sampled. We obtained 47 ex vivo biopsy cores from 14 primary ccRCC's (median tumor size 4.5 cm, IQR 4.0-5.9 cm). Branching patterns of various complexities were observed in tumors with three or more mutations. A VHL mutation was detected in nine tumors (64{\%}), each time being present ubiquitously throughout the tumor. Other genes had various degrees of regional mutational variation. Based on the mutations' prevalence we estimated that three different tumor regions should be sampled to detect mutations in PBRM1, SETD2, BAP1, and/or KDM5C with 90{\%} certainty. The mutational burden of renal tumors varies by region sampled. Single site assessment of key tumor suppressor mutations in primary ccRCC may not adequately capture the genetic predictors of tumor behavior.",
keywords = "Biomarker, genetic heterogeneity, kidney cancer, renal biopsy, renal cell carcinoma",
author = "Sankin, {Alexander I.} and Hakimi, {Abraham A.} and Nina Mikkilineni and Irina Ostrovnaya and Silk, {Mikhail T.} and Yupu Liang and Roy Mano and Michael Chevinsky and Motzer, {Robert J.} and Solomon, {Stephen B.} and Cheng, {Emily H.} and Durack, {Jeremy C.} and Coleman, {Jonathan A.} and Paul Russo and Hsieh, {James J.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1002/cam4.293",
language = "English (US)",
volume = "3",
pages = "1485--1492",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling

AU - Sankin, Alexander I.

AU - Hakimi, Abraham A.

AU - Mikkilineni, Nina

AU - Ostrovnaya, Irina

AU - Silk, Mikhail T.

AU - Liang, Yupu

AU - Mano, Roy

AU - Chevinsky, Michael

AU - Motzer, Robert J.

AU - Solomon, Stephen B.

AU - Cheng, Emily H.

AU - Durack, Jeremy C.

AU - Coleman, Jonathan A.

AU - Russo, Paul

AU - Hsieh, James J.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Primary clear cell renal cell carcinoma (ccRCC) genetic heterogeneity may lead to an underestimation of the mutational burden detected from a single site evaluation. We sought to characterize the extent of clonal branching involving key tumor suppressor mutations in primary ccRCC and determine if genetic heterogeneity could limit the mutation profiling from a single region assessment. Ex vivo core needle biopsies were obtained from three to five different regions of resected renal tumors at a single institution from 2012 to 2013. DNA was extracted and targeted sequencing was performed on five genes associated with ccRCC (von-Hippel Lindau [VHL], PBRM1, SETD2, BAP1, and KDM5C). We constructed phylogenetic trees by inferring clonal evolution based on the mutations present within each core and estimated the predictive power of detecting a mutation for each successive tumor region sampled. We obtained 47 ex vivo biopsy cores from 14 primary ccRCC's (median tumor size 4.5 cm, IQR 4.0-5.9 cm). Branching patterns of various complexities were observed in tumors with three or more mutations. A VHL mutation was detected in nine tumors (64%), each time being present ubiquitously throughout the tumor. Other genes had various degrees of regional mutational variation. Based on the mutations' prevalence we estimated that three different tumor regions should be sampled to detect mutations in PBRM1, SETD2, BAP1, and/or KDM5C with 90% certainty. The mutational burden of renal tumors varies by region sampled. Single site assessment of key tumor suppressor mutations in primary ccRCC may not adequately capture the genetic predictors of tumor behavior.

AB - Primary clear cell renal cell carcinoma (ccRCC) genetic heterogeneity may lead to an underestimation of the mutational burden detected from a single site evaluation. We sought to characterize the extent of clonal branching involving key tumor suppressor mutations in primary ccRCC and determine if genetic heterogeneity could limit the mutation profiling from a single region assessment. Ex vivo core needle biopsies were obtained from three to five different regions of resected renal tumors at a single institution from 2012 to 2013. DNA was extracted and targeted sequencing was performed on five genes associated with ccRCC (von-Hippel Lindau [VHL], PBRM1, SETD2, BAP1, and KDM5C). We constructed phylogenetic trees by inferring clonal evolution based on the mutations present within each core and estimated the predictive power of detecting a mutation for each successive tumor region sampled. We obtained 47 ex vivo biopsy cores from 14 primary ccRCC's (median tumor size 4.5 cm, IQR 4.0-5.9 cm). Branching patterns of various complexities were observed in tumors with three or more mutations. A VHL mutation was detected in nine tumors (64%), each time being present ubiquitously throughout the tumor. Other genes had various degrees of regional mutational variation. Based on the mutations' prevalence we estimated that three different tumor regions should be sampled to detect mutations in PBRM1, SETD2, BAP1, and/or KDM5C with 90% certainty. The mutational burden of renal tumors varies by region sampled. Single site assessment of key tumor suppressor mutations in primary ccRCC may not adequately capture the genetic predictors of tumor behavior.

KW - Biomarker

KW - genetic heterogeneity

KW - kidney cancer

KW - renal biopsy

KW - renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84990932171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990932171&partnerID=8YFLogxK

U2 - 10.1002/cam4.293

DO - 10.1002/cam4.293

M3 - Article

VL - 3

SP - 1485

EP - 1492

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 6

ER -